<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422396</url>
  </required_header>
  <id_info>
    <org_study_id>877-017</org_study_id>
    <nct_id>NCT00422396</nct_id>
  </id_info>
  <brief_title>Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis</brief_title>
  <official_title>Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <brief_summary>
    <textblock>
      This is a randomized placebo controlled clinical trial designed to investigate the effects of
      micronized fenofibrate on fasting and postprandial lipoproteins, oxidized fatty acids and
      lipoproteins, inflammatory mediators and thrombotic factors among hypertriglyceridemic
      individuals with two or more other characteristics of the metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to determine the effects of micronized fenofibrate (160 mg/daily)
      on:

        1. Fasting and postprandial lipids and lipoproteins after a standarized test meal.

        2. Fasting and postprandial oxidized fatty acids and oxidized low density lipoprotein after
           a standarized test meal.

        3. Fasting and postprandial inflammatory mediators after a standarized test meal.

        4. Fasting and postprandial lipopolysaccharide-stimulated cytokine production after a
           standarized test meal.

        5. Fasting and postprandial markers of hemostasis, fibrinolysis and blood viscosity after a
           standarized test meal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2001</start_date>
  <completion_date type="Actual">April 2002</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. lipids and lipoproteins</measure>
  </primary_outcome>
  <enrollment>60</enrollment>
  <condition>Hypertriglyceridemia With the Metabolic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. males and postmenopausal females 18 years of age with fasting triglycerides greater
             than or equal to 1.7 mmol/L and &lt;6.9 mmol/L

          2. two or more of the following Adult Treatment Panel III (1) criteria of the metabolic
             syndrome: abdominal obesity (waist circumference &gt;89 cm in females and &gt;102 cm in
             males); low high-density lipoprotein cholesterol (HDL-C) (&lt;1.3 mmol/L in women and
             &lt;1.0 mmol/L in men); hypertension (systolic blood pressure &gt;130 or diastolic blood
             pressure &gt;85 mm Hg) or current drug therapy for hypertension; and impaired fasting
             glucose (between 6.1 mmol/L and 7.0 mmol/L).

        Exclusion Criteria:

          1. included types 1 or 2 diabetes

          2. Body mass index &gt;40 kg/m2

          3. Use of lipid-lowering therapies

          4. Oral hypoglycemic therapies

          5. Insulin

          6. Aspirin &gt;81 mg daily

          7. Regular use of non-steroidal anti-inflammatory agents or cyclooxygenase-2 inhibitors,
             corticosteroids (oral and inhaled), anti-oxidants (including multivitamins), herbal or
             fiber supplements recent changes in type or formulation of hormone replacement therapy
             (in the last 6 months)

          8. Alcohol intake &gt;3 drinks per day

          9. Untreated hypothyroidism or recent change (within 2 months) of thyroid replacement
             therapy

         10. Cigarette smoking (current or within the last 6 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Rosenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University preventive Cardiology Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertrigliceridemia</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Obesity</keyword>
  <keyword>Fenofibrate</keyword>
  <keyword>Lipoproteins</keyword>
  <keyword>Cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

